36 completed. 36 Phase 2, 10 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 36 | Completed 36 |
| Phase 1 | 10 | Completed 10 |
| Phase 3 | 1 | Completed 1 |
Follow Tongue Diseases: new trials by email Literature Review of Tongue Diseases trials Research Report on Tongue Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Effectiveness of the Selected Method of Treatment of Primary Burning Mouth Syndrome Clonazepam tablets, tongue pads - Burning Mouth Syndrome, Glossodynia | Phase 2 | Completed | Wroclaw Medical University | 58 | 2019-01-12 | 2021-07-22 |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
| S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis Isatuximab, Laboratory Biomarker Analysis - Amorphous, Eosinophilic, and Acellular Deposit, Constipation | Phase 2 | Completed | SWOG Cancer Research Network | 43 | 2018-06-06 | 2025-09-09 |
| High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer High-activity natural killer - Tongue Cancer | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 20 | 2016-12-01 | 2019-09-12 |
| Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer Cryosurgery, NK immunotherapy - Recurrent Tongue Cancer | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2016-07-01 | 2019-09-12 |
| Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer Cisplatin, IMRT 6 weeks, IMRT 5 weeks - Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Completed | NRG Oncology | 316 | 2014-10-01 | 2026-05-22 |
| Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy acetylcysteine, placebo, quality-of-life assessment - Mucositis, Oral Complications | Phase 2 | Completed | Mayo Clinic | 34 | 2014-04-01 | 2019-04-30 |
| Inulin and S. Salivarius Reduce Halitosis Inulin+SS, S salivarius, Placebo - Halitosis, Tongue Diseases | Phase 2 | Completed | Universidade de Passo Fundo | 45 | 2014-03-01 | 2020-08-19 |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PI3K inhibitor BKM120, cetuximab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 / Phase 2 | Completed | University of Chicago | 12 | 2013-05-01 | 2021-10-05 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer cetuximab, paclitaxel, carboplatin - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | Fox Chase Cancer Center | 24 | 2011-02-16 | 2018-02-26 |
| Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Cetuximab, Laboratory Biomarker Analysis, Temsirolimus - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 86 | 2010-11-01 | 2017-03-27 |
| Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel - Head and Neck Cancer, Precancerous Condition | Phase 2 | Completed | Eastern Cooperative Oncology Group | 90 | 2010-08-11 | 2023-06-28 |
| Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Laboratory Biomarker Analysis, Vorinostat - Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2010-08-06 | 2020-08-03 |
| Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Sirolimus - Mouth Neoplasms, Head and Neck Neoplasms | Phase 1 / Phase 2 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 37 | 2010-08-01 | 2017-12-06 |
| Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery carboplatin, RAD001, paclitaxel - Head and Neck Cancer | Phase 1 / Phase 2 | Completed | GERCOR - Multidisciplinary Oncology Cooperative Group | 49 | 2009-10-01 | 2016-02-10 |
| Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Laboratory Biomarker Analysis, Soy Isoflavones, Survey Administration - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2009-07-01 | 2016-10-24 |
| Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab cetuximab, placebo, sorafenib tosylate - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2009-07-01 | 2026-03-10 |
| Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer Cetuximab, Cisplatin, Nab-Paclitaxel - Head and Neck Cancer | Phase 1 / Phase 2 | Completed | University of Texas Southwestern Medical Center | 37 | 2009-03-01 | 2020-08-21 |
| Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer cetuximab, cisplatin, intensity-modulated radiation therapy - Head and Neck Cancer | Phase 2 | Completed | University of Texas Southwestern Medical Center | 37 | 2008-12-01 | 2020-08-21 |
Showing 20 of 36. Sign in to see all of them.
Tongue Neoplasms (33) · Squamous Cell Carcinoma of Head and Neck (22) · Salivary Gland Neoplasms (15) · Head and Neck Neoplasms (12) · Mouth Neoplasms (10) · Oropharyngeal Neoplasms (7) · Hypopharyngeal Neoplasms (6) · Laryngeal Neoplasms (6) · Nasopharyngeal Neoplasms (5) · Carcinoma, Renal Cell (3) · Lymphoid Interstitial Pneumonia (3) · Pancreatic Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Squamous Cell (2)
Mouth Diseases (36) · Stomatognathic Diseases (36) · Neoplasms (34) · Neoplasms by Site (33) · Neoplasms by Histologic Type (27) · Carcinoma (26) · Neoplasms, Glandular and Epithelial (26) · Mouth Neoplasms (23) · Carcinoma, Squamous Cell (21) · Head and Neck Neoplasms (21) · Salivary Gland Diseases (15) · Otorhinolaryngologic Diseases (9) · Otorhinolaryngologic Neoplasms (9) · Pharyngeal Diseases (9)
Cetuximab (9) · Cisplatin (7) · Radiotherapy, Intensity-Modulated (5) · Paclitaxel (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · Carboplatin (2) · Sirolimus (2) · Sorafenib (2) · Acetylcysteine (1) · Bevacizumab (1) · Bortezomib (1) · Celecoxib (1) · Chemoprevention (1) · Clonazepam (1)
National Cancer Institute (NCI) (13) · Fox Chase Cancer Center (2) · Fuda Cancer Hospital, Guangzhou (2) · GERCOR - Multidisciplinary Oncology Cooperative Group (2) · University of Texas Southwestern Medical Center (2) · Centre Antoine Lacassagne (1) · Eastern Cooperative Oncology Group (1) · Klus Pharma Inc. (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · NRG Oncology (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · Ohio State University Comprehensive Cancer Center (1) · Radiation Therapy Oncology Group (1) · SWOG Cancer Research Network (1)
United States (29) · Canada (3) · China (3) · France (3) · Ireland (1) · Poland (1) · Saudi Arabia (1)
Jill Gilbert (2) · Tanguy Seiwert (2) · Amit Agrawal (1) · Barbara Burtness (1) · Christopher Thomas (1) · David G. Pfister, MD (1) · Emma Scott (1) · Fernando Fornari (1) · Frank Meyskens (1) · Gary G. Schwartz, MD, PhD, MPH (1) · Gary L. Clayman (1) · Greg Wolf (1) · Hak Choy, MD (1) · James Rocco (1) · Janice S Lee, DDS, MD (1)
PMID 25057165, PMID 14520092, PMID 22252927, PMID 23639862, PMID 25684313, PMID 25965900, PMID 26062933, PMID 26611425, PMID 28029303, PMID 29346519, PMID 30850872, PMID 31405750, PMID 33507809, PMID 40166973, PMID 40925099
U10CA021115 (2), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), N01CM62202 (1), N01CM62206 (1), P30CA006516 (1), P30CA006927 (1), P30CA014599 (1), P30CA015083 (1), P30CA016672 (1), P30CA022453 (1), P30CA046592 (1), P30CA076292 (1)